Global Uterine Cancer Market Spotlight 2017-2026: Key Pipeline Drugs, Clinical Trials, Patent Information, Disease Incidence Forecasts and Licensing and Acquisition Deals – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Uterine Cancer” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the uterine cancer market,
comprising key pipeline drugs, clinical trials, patent information, a
10-year disease incidence forecast, recent events and analyst opinion,
key upcoming events, probability of success, and licensing and
acquisition deals.

Key Takeaways

• The report estimates that in 2017, there were 377,900 incident cases
  of uterine cancer in females aged 15 years and over worldwide, and
  expects that number to increase to 413,600 incident cases by 2026.
• In the same year, there were an estimated 1.3 million five-year
  prevalent cases of uterine cancer worldwide, which is expected to
  increase slightly to 1.4 million by 2026.
• The majority of industry-sponsored drugs in active clinical
  development for uterine cancer are in Phase II, with only three drugs
  in Phase III.
• Therapies in mid-to-late-stage development for uterine cancer focus on
  a wide variety of targets. The majority of pipeline drugs are
  administered orally, with three drugs being tested in intravenous
  formulations.
• High-impact upcoming events for drugs in the uterine cancer space
  comprise topline Phase II trial results for XBIO-101, and an estimated
  patent expiration for Ixempra.
• The overall likelihood of approval of a Phase I solid tumors asset is
  5.7%, and the average probability a drug advances from Phase III is
  39.4%. Drugs, on average, take 9.5 years from Phase I to approval,
  compared to 9.2 years in the overall oncology space.
• There have been seven licensing and asset acquisition deals involving
  endometrial cancer drugs during 2013-18. The $1,657m collaboration and
  exclusive license agreement in 2014 between AnaptysBio and Tesaro,
  pursuant to which Tesaro was granted exclusive rights to antibody
  programs targeting PD-1, TIM-3, and LAG-3, including monospecific and
  dual reactive antibody drug candidates, was the largest deal during
  the period.
• The clinical trials distribution across Phase I-IV indicates that the
  vast majority of trials for uterine neoplasms have been in the early
  and mid-phases of development, with 97% of trials in Phase I-II, and
  only 3% in Phase IV.
• The US has a substantial lead in the number of uterine neoplasms
  clinical trials globally, while Germany and Spain lead the major EU
  markets.
• Sanofi has the highest number of completed clinical trials for uterine
  neoplasms, with six trials. Sanofi leads industry sponsors with the
  highest number of overall clinical trials for uterine neoplasms,
  followed by AstraZeneca and Eli Lilly

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

Surgery

Radiation therapy

Chemotherapy

Hormone therapy

Palliative care

EPIDEMIOLOGY

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

Keytruda for Uterine Cancer (March 7, 2018)

Lenvima for Uterine Cancer (March 7, 2018)

GALE-301 for Uterine Cancer (March 15, 2017)

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

Keytruda/Lenvima Gets Breakthrough Designation With Basket Trial

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

Eisai And Merck & Co Supercharge Lenvima’s Potential

PARENT PATENTS

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/szp9qu

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Women’s
Health